Sandi's story
Choosing a breast cancer treatment is not an easy decision to make. That's why it's so important to talk it over with your doctor. In this video, you'll meet Sandi, a breast cancer survivor, as she talks about her treatment options. You will also hear from a leading expert in the field of breast cancer, Dr. William J. Gradishar.
The end of the video introduces some support groups and their important role in breast cancer treatment.
Please note that Sandi is not Dr. Gradishar’s patient.
Select a chapter to begin viewing the video.
AROMASIN® (exemestane tablets) is a prescription medicine for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer. Treatment with AROMASIN should begin after 2 to 3 years of tamoxifen, at which time tamoxifen should be discontinued. Treatment with AROMASIN should continue for 2 to 3 years (until the completion of a total of 5 years of adjuvant treatment with tamoxifen and AROMASIN).
Copyright © 2009 Pfizer Inc. All rights reserved.
The product information provided in this site is intended only for residents of
the United States. The products discussed herein may have different product labeling
in different countries.
The health information herein is provided for educational purposes only and is not
intended to replace discussions with a health care provider. All decisions regarding
patient care must be made with a health care provider, considering the unique characteristics
of the patient.
AOU00471
